Diligence memo · auto-generated · as of July 2, 2026
Stagezero Life Sciences Ltd.
Stagezero Life Sciences Ltd. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Stagezero Life Sciences Ltd. operates in Biotechnology, based in RICHMOND HILL.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Stagezero Life Sciences Ltd. has raised $27M in disclosed capital across 13 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.3M on 2012-12-14.
Most recent recorded round closed around 2022-03-02.
Valuation (modeled)modeled
Provath models Stagezero Life Sciences Ltd. at approximately $24M (range $1.6M–$88M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Issuer reports $5M–$25M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 73% of Biotechnology peers (4293 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.